The debate on rare diseases involving public health experts, politicians, and economists often focuses on the budget impact from the public health systems' and private health plans' incorporation of so-called orphan drugs. Since such drugs are limited to a reduced target public and require high investment in technological research for their development, they are scarcely profitable and bear little or no interest to pharmaceutical companies. This is certainly an important issue, but there are other dimensions to the economic and social impact of rare diseases that require attention.
Some 250 new rare diseases are described every year due to the refinement of knowledge on pathophysiology and genomics. Thus, rare diseases are not all that rare, especially considering the total number of persons affected by these various diseases. Technological development in recent decades has created the possibility of treatment for many rare diseases. Associations of patients living with these diseases and health activists have propelled research for the development of new drugs. However, access to the drug is not enough, as clearly shown by Pinto et al. It is necessary to guarantee that the best care is offered. This requires more than monetary incentives. It is necessary to support and enable the caregivers' intense journey of dedication.
The United Nations' 2030 Agenda for Sustainable Development 2 proposes "to leave no one behind". Gender, social, racial, and religious inequities must be overcome. The article by Pinto et al. gives us food for thought on many of these inequities. Only a debate involving academic institutions, decision-makers, regulatory agencies, the pharmaceutical industry, and especially civil society through individual empowerment and advocacy associations 3, 4 ,5 can answer the remaining questions: Who in fact is the orphan -the drug, the disease, or the affected family? Who should pay the bill? Which costs should be presented -in addition to the financial costs?
